Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (GLTO) is a clinical-stage biotechnology company at the forefront of developing innovative treatments for fibrosis and cancer. Founded in Lund, Sweden, and now incorporated in the U.S., Galecto focuses on small-molecule inhibitors targeting galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins integral to the pathology of fibrosis and various cancers.
The company's lead product candidates include GB0139, GB1211, and GB2064. GB0139, initially developed for idiopathic pulmonary fibrosis (IPF), has shown promising preclinical results but recently failed to meet its primary endpoint in the Phase 2b GALACTIC-1 trial. Consequently, Galecto will discontinue its development and redirect resources.
GB1211, a selective oral galectin-3 inhibitor, targets severe liver diseases like non-alcoholic steatohepatitis (NASH) and liver cirrhosis. Encouraging results from the GULLIVER-2 trial underscored significant biomarker improvements and a favorable safety profile, setting the stage for the upcoming Phase 2a GULLIVER-3 trial in early 2024.
GB2064, an oral LOXL2 inhibitor, is in Phase 2a trials for myelofibrosis. Preliminary data indicate significant reductions in bone marrow fibrosis, validating the compound’s potential as a disease-modifying therapy.
Galecto's strategic partnerships and collaborations with top-tier scientists and biotech executives position it well for future growth. The company is also exploring GB1211's potential in oncology, specifically in combination with checkpoint inhibitors to overcome treatment resistance in cancers like non-small cell lung cancer (NSCLC) and melanoma.
With approximately $49 million in cash and investments, Galecto aims to extend its cash runway into 2025, focusing on advancing its promising pipeline of orally administered compounds.
For the latest updates and detailed information about Galecto, visit their website at www.galecto.com.
Galecto, Inc. (NASDAQ: GLTO) has initiated a Phase 2a trial for its oral LOXL2 inhibitor, GB2064, aimed at treating myelofibrosis, a rare blood cancer. The MYLOX-1 trial will evaluate safety, tolerability, and the drug's effects on fibrosis in 16 patients over 9 months. Galecto's CEO highlighted the unmet medical need in myelofibrosis, where current treatment options are limited. Previously, GB2064 showed no safety issues in a Phase 1 study with healthy volunteers. With LOXL2 being a crucial target in fibrosis, this trial may offer new therapeutic hope.
Galecto, Inc. (NASDAQ: GLTO) reported its Q2 2021 financial results, highlighting ongoing advancements in its fibrosis and cancer treatment pipelines. The company resumed recruitment for its GALACTIC-1 Phase 2b trial of GB0139, an inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis, after regulatory approval. Recent results indicated GB0139's efficacy in COVID-19 patients with compromised lung function. Financially, Galecto held $138 million in cash and equivalents, with R&D expenses increasing to $8.6 million due to clinical activities. The net loss for the quarter was $12.3 million, or $(0.49) per share.
Galecto, Inc. (NASDAQ: GLTO) has resumed recruitment for its Phase 2b GALACTIC-1 trial of GB0139, an inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). The revised protocol allows recruitment of patients not currently on nintedanib or pirfenidone. The trial will assess safety and efficacy over 52 weeks, with topline results expected by mid-2023. Previous studies showed GB0139 was well-tolerated and demonstrated significant effects on fibrosis biomarkers. The company aims to address the unmet medical need for IPF treatments, as 50% of patients in Europe and the US do not receive existing therapies.
Galecto, Inc. (NASDAQ: GLTO) announced positive preliminary results from a trial of its inhaled galectin-3 inhibitor, GB0139, in patients with COVID-19. The trial, involving 41 patients, demonstrated that GB0139 significantly reduced oxygen flow requirements and improved biomarkers related to lung and systemic inflammation, liver function, and coagulation. A 21% reduction in mortality was observed in the post-hoc analysis for moderate to severe cases. The company will redirect resources towards four ongoing Phase 2 trials focusing on fibrosis and cancer while exploring partnerships for further COVID-19 research.
Galecto, Inc. (GLTO) will host a KOL webinar on June 9, 2021, at 8am ET, focusing on the treatment landscape for myelofibrosis. The event will feature Dr. Srdan Verstovsek, who will discuss current treatments and opportunities for Galecto's GB2064, an oral LOXL2 inhibitor targeted at myelofibrosis. Galecto’s President will also provide updates on development status. As myelofibrosis treatments face limitations, GB2064 represents a potential advance. Registration details for the webinar can be found on their website.
Galecto, Inc. (NASDAQ: GLTO) has appointed Garrett Winslow as Senior Vice President and General Counsel. Winslow, with over 15 years of experience in the life sciences sector, will oversee legal, compliance, and enterprise risk management, reporting directly to CEO Hans Schambye. Previously, he was General Counsel at Spring Bank Pharmaceuticals and a partner at Mintz. His expertise is expected to strengthen Galecto's clinical development pipeline. The company is focused on developing novel therapies for fibrosis and cancer, with clinical programs advancing in 2021.
Galecto, Inc. (NASDAQ: GLTO) will host a key opinion leader event on June 9, 2021, to address the treatment landscape and unmet needs in myelofibrosis. The event will feature discussions on GB2064, a LOXL2 inhibitor entering phase 2 trials. Prior to this, executives will participate in investor conferences, including the Bank of America Securities Virtual Healthcare Conference on May 12 and Jefferies Virtual Healthcare Conference on June 3. Live webcasts of these events will be available on Galecto's website.
Galecto, Inc. (NASDAQ: GLTO) reported Q1 2021 financial results, highlighting a net loss of $13.3 million, or $(0.53) per share, compared to $5.7 million, or $(21.83) per share, in Q1 2020. The company is advancing its pipeline with plans for three Phase 2 clinical trials, namely MYLOX-1 for myelofibrosis, GALLANT-1 for non-small cell lung cancer, and GULLIVER-2 for liver cirrhosis. As of March 31, 2021, Galecto had $149 million in cash, expected to fund operations into 2024. R&D expenses rose to $10 million from $4.7 million due to increased clinical spending.
Galecto announced a publication in the Gastric Cancer journal highlighting the role of galectin-3 in gastric cancer progression. The study suggests that high levels of galectin-3 correlate with poor prognosis in patients. The preclinical research indicates that GB1107, a galectin-3 inhibitor, effectively inhibits tumor growth in mouse models. The company plans to initiate clinical studies for GB1211, another galectin-3 inhibitor, targeting Non-Small-Cell Lung Cancer and other cancer types.
Galecto, Inc. (GLTO) reported its 2020 operating and financial results, highlighting a successful IPO raising $160 million. Cash reserves stood at approximately $164 million, expected to fund operations into 2024. R&D expenses rose to $24.6 million, driven by the GALACTIC-1 study. The net loss decreased to $34.8 million, or $(7.62) per share, improving from $(161.82) in 2019. Galecto aims to initiate three Phase 2 trials in 2021 and continues to advance the GALACTIC-1 trial in Idiopathic Pulmonary Fibrosis (IPF) to address unmet treatment needs.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
What does Galecto, Inc. specialize in?
What are Galecto's key product candidates?
Why is Galecto discontinuing GB0139?
What are the next steps for GB1211?
What recent achievements has Galecto made?
How is GB1211 expected to help cancer patients?
What is Galecto's financial condition?
Where is Galecto headquartered?
Who leads Galecto, Inc.?
Where can I find more information about Galecto?
